Vascular endothelial growth factor suppresses dendritic cells function of human prostate cancer

OncoTargets and Therapy, Mar 2018

Vascular endothelial growth factor suppresses dendritic cells function of human prostate cancer Wen-kun Bai, Wei Zhang, Bing Hu Department of Ultrasound in Medicine, Shanghai Jiao Tong University Affiliated 6th People’s Hospital, Shanghai Institute of Ultrasound in Medicine, Shanghai, China Purpose: Prostate cancer (PCa) patients often have dendritic cell (DC) function defects, but the mechanism is not clear. The aim of this study was to detect the effect of vascular endothelial growth factor (VEGF) in mature DCs. Patients and methods: In this study, we chose 30 PCa patients, 10 prostatic intraepithelial neoplasia (PIN) patients and 30 benign prostatic hyperplasia (BPH) patients, and compared the composition of peripheral blood T cells, the composition and function of local dendritic cells in prostate tissue, and the density of local VEGF. Results: The results showed that the numbers of total DCs, mature and functional DCs, and CD4+ T cells were inhibited in PCa, and the inhibitory effect was enhanced with increased malignancy. In addition, the infiltration density of VEGF-positive cells was increased in PCa, and this increase was associated with an increased malignant degree of PCa. The inhibition of tumor immunity in patients with PCa is achieved by inhibiting the function of dendritic cells. Conclusion: VEGF plays an important role in the inhibition of the maturation and function of dendritic cells, and this inhibition is gradually increased with an increasing malignant degree of PCa. Keywords: prostate cancer, vascular endothelial growth factor, dendritic cell, immunology, T cell

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://www.dovepress.com/getfile.php?fileID=40824

Vascular endothelial growth factor suppresses dendritic cells function of human prostate cancer

OncoTargets and Therapy Vascular endothelial growth factor suppresses dendritic cells function of human prostate cancer 0 Wen-kun Bai Wei Zhang Bing hu 8 1 0 2 - l u J - 2 1 n o 7 0 2 . 6 4 . 9 5 . 7 3 y b / m o c . s s re . .vdoep lsyeon w u /ww lan /: o tsp rse th rp PowerdbyTCPDF(ww.tcpdf.org) O r i g i n a l r e s e a r c h Purpose: Prostate cancer (PCa) patients often have dendritic cell (DC) function defects, but the mechanism is not clear. The aim of this study was to detect the effect of vascular endothelial growth factor (VEGF) in mature DCs. Patients and methods: In this study, we chose 30 PCa patients, 10 prostatic intraepithelial neoplasia (PIN) patients and 30 benign prostatic hyperplasia (BPH) patients, and compared the composition of peripheral blood T cells, the composition and function of local dendritic cells in prostate tissue, and the density of local VEGF. Results: The results showed that the numbers of total DCs, mature and functional DCs, and CD4+ T cells were inhibited in PCa, and the inhibitory effect was enhanced with increased malignancy. In addition, the infiltration density of VEGF-positive cells was increased in PCa, and this increase was associated with an increased malignant degree of PCa. The inhibition of tumor immunity in patients with PCa is achieved by inhibiting the function of dendritic cells. Conclusion: VEGF plays an important role in the inhibition of the maturation and function of dendritic cells, and this inhibition is gradually increased with an increasing malignant degree of PCa. - Department of Ultrasound in Medicine, shanghai Jiao Tong University a ffiliated 6th People’s hospital, shanghai institute of Ultrasound in Medicine, shanghai, china Early theories did not consider the prostate to be an organ monitored by the body’s immune system,5 but nearly 7 years of research has overthrown this viewpoint, suggesting that the treatment of PCa may potentially work by activating the immune system.6 Therefore, increasing attention to the clinical treatment of PCa, especially in late androgenindependent or distant metastasis, focuses on activating the human immune system to treat PCa. Sipuleucel-T was 2108 approved by the United States Food and Drug Administration l--Ju for PCa therapy in 2010.7 12 Previous studies have demonstrated that the quantity and 7no activity of DCs in PCa patients are significantly lower than .602 in healthy controls,8 and in vitro experiments verified that .459 PCa cells induce apoptosis, as well as suppress the regenera.73 tion and differentiation of DCs.9 Studies also showed that /yb the numbers of DCs are reduced in PCa tissues compared .com to prostatic hyperplasia (BPH) tissues, and the levels of s re . infiltrating DCs are further decreased with the advancement s .vdoepw lsyeonu tohfeastyypmiap.t1o0mCsurirneandtvimanmceudnoPtChearpapatiieesnatrseacnodncfainnendottocurerleiethvee /ww lan disease, and the immunosuppressive tumor microenviron/: o tsp rse ment may limit their effectiveness.11 Therefore, it is necestrohm ropF sary to determine the mechanism of immune inhibition to fd overcome the immune restriction and improve the efficacy aed of immunotherapy. lonw Vascular endothelial growth factor (VEGF), which ydo induces neoangiogenesis and the blockade of angiogenesis, reap plays an important role in the development and metastasis hT of solid tumors, and targeting VEGF has become a useful nad approach in cancer therapy.12 The inhibition of VEGF in trseg a mouse model leads to increased antigen uptake and the oaT migration of tumor-associated DCs.13 In the human tongue cnO carcinoma, cancer cells could be inhibited in proliferation and be increased in apoptosis by knocking down the expression of VEGF, and maturation of DCs also could be improved.14 VEGF also influences the effect of DCs on therapy in the model of colon cancer-induced malignant ascites.15 VEGF expression in the peripheral blood and neoplasm nest from patients with oral squamous cell carcinoma (OSCC) was positively correlated with the course of the disease, while an inverse correlation between VEGF expression and DCs was identified in the peripheral blood.14 Some clinical research has been carried out that blocks VEGF to improve the antitumor responses in treating PCa patients.16 PCa is divided into three categories, which fit the following standard definitions: low-risk PCa (biopsy Gleason grade  7 or prostate-specific antigen (PSA)  10 ng/mL), intermediate-risk PCa (biopsy Gleason score 7 or PSA 10–20 ng/mL), and high-risk PCa submit your manuscript | www.dovepress.com Dovepress (biopsy Gleason score  7 or PSA  20 ng/mL).17–20 Determining the status of DC and VEGF expression in different degrees of PCa patients is needed. In this study, we compared the composition and functional status of DCs in prostate tissues of patients with BPH, prostatic intraepithelial neoplasia (PIN) and PCa and compared the expression of VEGF in these prostate tissues. We also compared (...truncated)


This is a preview of a remote PDF: https://www.dovepress.com/getfile.php?fileID=40824

Wen-kun Bai, Wei Zhang, Bing Hu. Vascular endothelial growth factor suppresses dendritic cells function of human prostate cancer, OncoTargets and Therapy, 2018, pp. 1267-1274, DOI: 10.2147/OTT.S161302